Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wolfgang Vahrson is active.

Publication


Featured researches published by Wolfgang Vahrson.


Journal of Clinical Microbiology | 2004

SYBR Green-Based Real-Time Quantitative PCR Assay for Detection of West Nile Virus Circumvents False-Negative Results Due to Strain Variability

James F. Papin; Wolfgang Vahrson; Dirk P. Dittmer

ABSTRACT Real-time quantitative PCR is used routinely for the high-throughput diagnosis of viral pathogens, such as West Nile virus (WNV). Rapidly evolving RNA viruses present a challenge for diagnosis because they accumulate mutations that may render them undetectable. To explore the effect of sequence variations on assay performance, we generated every possible single point mutation within the target region of the widely used TaqMan assay for WNV and found that the TaqMan assay failed to detect 47% of possible single nucleotide variations in the probe-binding site and was unable to detect any targets with more than two mutations. In response, we developed and validated a less expensive assay with the intercalating dye SYBR green. The SYBR green-based assay was as sensitive as the TaqMan assay for WNV. Importantly, it detected 100% of possible WNV target region variants. The assay developed here adds an additional layer of protection to guard against false-negative results that result from natural variations or drug-directed selection and provides a rapid means to identify such variants for subsequent detailed analysis.


Nucleic Acids Research | 2005

Faster quantitative real-time PCR protocols may lose sensitivity and show increased variability

Chelsey Hilscher; Wolfgang Vahrson; Dirk P. Dittmer

Quantitative real-time PCR has become the method of choice for measuring mRNA transcription. Recently, fast PCR protocols have been developed as a means to increase assay throughput. Yet it is unclear whether more rapid cycling conditions preserve the original assay performance characteristics. We compared 16 primer sets directed against Epstein–Barr virus (EBV) mRNAs using universal and fast PCR cycling conditions. These primers are of clinical relevance, since they can be used to monitor viral oncogene and drug-resistance gene expression in transplant patients and EBV-associated cancers. While none of the primers failed under fast PCR conditions, the fast PCR protocols performed worse than universal cycling conditions. Fast PCR was associated with a loss of sensitivity as well as higher variability, but not with a loss of specificity or with a higher false positive rate.


Methods of Molecular Biology | 2005

Real-Time Quantitative PCR Analysis of Viral Transcription

James F. Papin; Wolfgang Vahrson; Rebecca Hines-Boykin; Dirk P. Dittmer

Whole-genome profiling using DNA arrays has led to tremendous advances in our understanding of cell biology. It has had similar success when applied to large viral genomes, such as the herpesviruses. Unfortunately, most DNA arrays still require specialized and expensive resources and, generally, large amounts of input RNA. An alternative approach is to query entire viral genomes using real-time quantitative PCR. We have designed such PCR-based arrays for every open reading frame of human herpesvirus 8 and describe here the general design criteria, validation procedures, and detailed application to quantify viral mRNAs. This should provide a useful resource either for whole-genome arrays or just to measure transcription of any one particular mRNA of interest. Because these arrays are RT-PCR-based, they are inherently more sensitive and robust than current hybridization-based approaches and are ideally suited to query viral gene expression in models of pathogenesis.


Mbio | 2014

Viral Profiling Identifies Multiple Subtypes of Kaposi’s Sarcoma

Mina C. Hosseinipour; Kristen M. Sweet; Jie Xiong; Dan Namarika; Albert Mwafongo; Michael Nyirenda; Loreen Chiwoko; Deborah Kamwendo; Irving Hoffman; Jeannette Y. Lee; Sam Phiri; Wolfgang Vahrson; Blossom Damania; Dirk P. Dittmer

ABSTRACT Kaposi’s sarcoma (KS), caused by KS-associated herpesvirus (KSHV), is the most common cancer among HIV-infected patients in Malawi and in the United States today. In Malawi, KSHV is endemic. We conducted a cross-sectional study of patients with HIV infection and KS with no history of chemo- or antiretroviral therapy (ART). Seventy patients were enrolled. Eighty-one percent had T1 (advanced) KS. Median CD4 and HIV RNA levels were 181 cells/mm3 and 138,641 copies/ml, respectively. We had complete information and suitable plasma and biopsy samples for 66 patients. For 59/66 (89%) patients, a detectable KSHV load was found in plasma (median, 2,291 copies/ml; interquartile range [IQR], 741 to 5,623). We utilized a novel KSHV real-time quantitative PCR (qPCR) array with multiple primers per open reading frame to examine KSHV transcription. Seventeen samples exhibited only minimal levels of KSHV mRNAs, presumably due to the limited number of infected cells. For all other biopsy samples, the viral latency locus (LANA, vCyc, vFLIP, kaposin, and microRNAs [miRNAs]) was transcribed abundantly, as was K15 mRNA. We could identify two subtypes of treatment-naive KS: lesions that transcribed viral RNAs across the length of the viral genome and lesions that displayed only limited transcription restricted to the latency locus. This finding demonstrates for the first time the existence of multiple subtypes of KS lesions in HIV- and KS-treatment naive patients. IMPORTANCE KS is the leading cancer in people infected with HIV worldwide and is causally linked to KSHV infection. Using viral transcription profiling, we have demonstrated the existence of multiple subtypes of KS lesions for the first time in HIV- and KS-treatment-naive patients. A substantial number of lesions transcribe mRNAs which encode the viral kinases and hence could be targeted by the antiviral drugs ganciclovir or AZT in addition to chemotherapy. KS is the leading cancer in people infected with HIV worldwide and is causally linked to KSHV infection. Using viral transcription profiling, we have demonstrated the existence of multiple subtypes of KS lesions for the first time in HIV- and KS-treatment-naive patients. A substantial number of lesions transcribe mRNAs which encode the viral kinases and hence could be targeted by the antiviral drugs ganciclovir or AZT in addition to chemotherapy.


International Journal of Cancer | 2012

Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies

Juan Carlos Ramos; Sang Hoon Sin; Michelle R. Staudt; Debasmita Roy; Wolfgang Vahrson; Bruce J. Dezube; William J. Harrington; Dirk P. Dittmer

The nuclear factor kappa B (NFκB) pathway is essential for many human cancers. Therapeutics such as bortezomib (Velcade™) that interfere with NFκB signaling are of great clinical interest. NFκB signaling, however, is multifaceted and variable among tissues, developmental and disease entities. Hence, targeted biomarkers of NFκB pathways are of prime importance for clinical research. We developed a novel real‐time qPCR‐based NFκB array. Only mechanistically validated NFκB targets were included. We then used random‐forest classification to define individual genes and gene combinations within the NFκB pathways that define viral lymphoma subclasses as well as Kaposi sarcoma (KS). Few NFκB targets emerged that were universally present in all tumor types tested, underscoring the need for additional tumor‐type specific biomarker discovery. (i) We uncovered tissue of origin‐specific tumor markers, specifically CD69, CSF‐1 and complement factor B (C1QBP) for primary effusion lymphoma (PEL); IL1‐beta, cyclinD3 and CD48 for KS. We found that IL12, jun‐B, msx‐1 and thrombospondin 2 were associated with EBV co‐infection in PEL. (ii) We defined the NFκB signature of Epstein–Barr virus (EBV) positive AIDS‐associated Burkitt lymphoma (BL). This signature identified CCR5 as the key marker. (iii) This signature differed from EBV negative BL consistent with the idea that EBV not only activates NFκB activity but that this virus also reprograms NFκB signaling toward different targets.


Journal of Virological Methods | 2010

Genome-wide real-time PCR for West Nile virus reduces the false negative rate and facilitates new strain discovery

James F. Papin; Wolfgang Vahrson; Lindsay Larson; Dirk P. Dittmer

West Nile virus (WNV) causes significant morbidity and mortality worldwide. Transplant and transfusion recipients as well as the elderly are particularly at risk. WNV shows strain variation from season to season and from locale to locale. This poses a significant problem for diagnosis. Most assays use a single primer pair to detect WNV by QPCR, and can fail to detect novel stains. To overcome this limitation, a genome-wide, multiple primer-based real-time QPCR assay was developed for WNV. The same assay can be used for quantitation, viral variant discovery as well as for amplification of the entire viral genome using a single annealing temperature. It improves upon routine diagnosis as well as facilitates laboratory investigations of the pathology of WNV.


Blood | 2008

Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma

Andrea O'Hara; Wolfgang Vahrson; Dirk P. Dittmer


Aids Reviews | 2005

Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment.

Dirk P. Dittmer; Wolfgang Vahrson; Michelle R. Staudt; Chelsey Hilscher; Farnaz D. Fakhari


Cancer Genomics & Proteomics | 2004

Real-time Quantitative PCR Arrays for Virally-associated Cancers

Dirk P. Dittmer; Wolfgang Vahrson; Michelle R. Staudt; James F. Papin; Rebecca Hines-Boykin; Farnaz D. Fakhari


Archive | 2013

lymphoma changes contribute to the miRNA signature of primary effusion Gene alteration and precursor and mature microRNA transcription

Andrea O'Hara; Wolfgang Vahrson; Dirk P. Dittmer

Collaboration


Dive into the Wolfgang Vahrson's collaboration.

Top Co-Authors

Avatar

Dirk P. Dittmer

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

James F. Papin

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrea O'Hara

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Chelsey Hilscher

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Farnaz D. Fakhari

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Rebecca Hines-Boykin

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Albert Mwafongo

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Blossom Damania

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge